Summary I have chosen to summarize an article about a new antifungal called eberconazole. 20 to 25% of the world's population is affected by a dermatophyte infection. This is a parasitic skin infection caused by a fungus. The most common species of fungi that cause dermatophytosis are Trichophyton, Epidermophyton and Microsporum. It is caused by parasitic organisms that attach themselves to the keratin of the skin. They feed on keratin and form colonies. These infections are limited only to the superficial layers of the skin, so topical antifungal agents are an excellent treatment. Although oral and topical antifungals can be used, topical treatments are the drugs of choice for localized dermatophytosis due to a decrease in the amount of adverse reactions, greater efficacy and scope of treatment, shorter treatment period needed, ease of administration use and application, decreased treatment time and increased compliance. There are many antifungals on the market and choosing the best drug for treatment is made more difficult due to problems in diagnosing the infection, signs and symptoms that are not the norm for clinical presentation, the prevalence of drug-resistant strains , of the growing population of immunocompromised people and poor adherence to treatment. Eberconazole is an imidazole derivative originally launched on the market in Spain in 2005 by Laboratories Salvat and is now on the market in many countries. This article reviews the pharmacology of this drug, its clinical use and its effectiveness. The molecular structure of eberconazole is C18H14Cl2N2. It is a broad-spectrum antifungal that has been shown to be successful in combating dermatophytosis, candidiasis and other yeast infections including Malassezzia furfur... focus of the article... eberconazole beyond this article and looks like a promising drug for the future . It makes me want to continue following its emergence in the United States. It is currently used in many other countries besides the United States. You may encounter patients who may be using this drug because they obtained it elsewhere. The greater knowledge we have about drugs being studied or available in other countries can help us better treat patients who may be using these drugs. I will continue to watch for this drug to become available in the United States so I can use it in my practice one day. Works Cited Moodahadu-Bangera, L.S., Martis, J., Mittal, R., Krishnankutty, B., Kumar, N., Bellary, S., ... Rao, P.K. (2012). Eberconazole-Pharmacological and clinical review. Indian Journal of Dermatology, Venereology and Leprology, 78(2), 217-222.